{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:15:20Z","timestamp":1772781320509,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T00:00:00Z","timestamp":1306540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00262-011-1038-y","type":"journal-article","created":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T09:27:27Z","timestamp":1306488447000},"page":"1309-1317","source":"Crossref","is-referenced-by-count":29,"title":["Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN"],"prefix":"10.1007","volume":"60","author":[{"given":"S. M.","family":"Geary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Lubaroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,28]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"crossref","unstructured":"Farkas AM, Finn OJ (2010) Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol","DOI":"10.1016\/j.smim.2010.03.003"},{"key":"1038_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1359","volume":"4","author":"E Gilboa","year":"2004","unstructured":"Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401\u2013411","journal-title":"Nat Rev Cancer"},{"key":"1038_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1385\/IR:36:1:73","volume":"36","author":"OJ Finn","year":"2006","unstructured":"Finn OJ (2006) Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 36:73\u201382","journal-title":"Immunol Res"},{"key":"1038_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","volume":"9","author":"TA Waldmann","year":"2003","unstructured":"Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269\u2013277","journal-title":"Nat Med"},{"key":"1038_CR5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909\u2013915","journal-title":"Nat Med"},{"key":"1038_CR6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14760584.6.2.255","volume":"6","author":"M Liniger","year":"2007","unstructured":"Liniger M, Zuniga A, Naim HY (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6:255\u2013266","journal-title":"Expert Rev Vaccines"},{"key":"1038_CR7","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1371\/journal.ppat.0030025","volume":"3","author":"C Cheng","year":"2007","unstructured":"Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL et al (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3:e25","journal-title":"PLoS Pathog"},{"key":"1038_CR8","first-page":"5260","volume":"62","author":"G Miller","year":"2002","unstructured":"Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP (2002) Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 62:5260\u20135266","journal-title":"Cancer Res"},{"key":"1038_CR9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14712590903586213","volume":"10","author":"RJ Amato","year":"2010","unstructured":"Amato RJ (2010) 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 10:281\u2013287","journal-title":"Expert Opin Biol Ther"},{"key":"1038_CR10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005014605991","volume":"1","author":"MJ McCluskie","year":"2001","unstructured":"McCluskie MJ, Weeratna RD (2001) Novel adjuvant systems. Curr Drug Targets Infect Disord 1:263\u2013271","journal-title":"Curr Drug Targets Infect Disord"},{"key":"1038_CR11","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","volume":"117","author":"AM Krieg","year":"2007","unstructured":"Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117:1184\u20131194","journal-title":"J Clin Invest"},{"key":"1038_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-3083.2006.01706.x","volume":"63","author":"V Salucci","year":"2006","unstructured":"Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P et al (2006) CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 63:35\u201341","journal-title":"Scand J Immunol"},{"key":"1038_CR13","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.22873","volume":"121","author":"D Karan","year":"2007","unstructured":"Karan D, Krieg AM, Lubaroff DM (2007) Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 121:1520\u20131528","journal-title":"Int J Cancer"},{"key":"1038_CR14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","volume":"54","author":"MW Moore","year":"1988","unstructured":"Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777\u2013785","journal-title":"Cell"},{"key":"1038_CR15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00262-008-0648-5","volume":"58","author":"AS Giermasz","year":"2009","unstructured":"Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL et al (2009) Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58:1329\u20131336","journal-title":"Cancer Immunol Immunother"},{"key":"1038_CR16","first-page":"6287","volume":"52","author":"F Zhou","year":"1992","unstructured":"Zhou F, Rouse BT, Huang L (1992) Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res 52:6287\u20136291","journal-title":"Cancer Res"},{"key":"1038_CR17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/1097-0215(20000801)87:3<427::AID-IJC18>3.0.CO;2-J","volume":"87","author":"TS Kim","year":"2000","unstructured":"Kim TS, Chung SW, Kim SH, Kang SN, Kang BY (2000) Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion. Int J Cancer 87:427\u2013433","journal-title":"Int J Cancer"},{"key":"1038_CR18","first-page":"3486","volume":"55","author":"K Hariharan","year":"1995","unstructured":"Hariharan K, Braslawsky G, Black A, Raychaudhuri S, Hanna N (1995) The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 55:3486\u20133489","journal-title":"Cancer Res"},{"key":"1038_CR19","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.vaccine.2003.12.015","volume":"22","author":"SW Chung","year":"2004","unstructured":"Chung SW, Cohen EP, Kim TS (2004) Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Vaccine 22:2547\u20132557","journal-title":"Vaccine"},{"key":"1038_CR20","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1158\/0008-5472.CAN-05-0406","volume":"65","author":"W Song","year":"2005","unstructured":"Song W, Levy R (2005) Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 65:5958\u20135964","journal-title":"Cancer Res"},{"key":"1038_CR21","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.4049\/jimmunol.171.8.3941","volume":"171","author":"AS Lonsdorf","year":"2003","unstructured":"Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV et al (2003) Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171:3941\u20133946","journal-title":"J Immunol"},{"key":"1038_CR22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ijc.1556","volume":"94","author":"BD Elzey","year":"2001","unstructured":"Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM (2001) Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 94:842\u2013849","journal-title":"Int J Cancer"},{"key":"1038_CR23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","volume":"18","author":"J Banchereau","year":"2000","unstructured":"Banchereau J, Briere F, Caux C, Davoust J, Lebecque S et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767\u2013811","journal-title":"Annu Rev Immunol"},{"key":"1038_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jdermsci.2007.03.002","volume":"46","author":"K Mahnke","year":"2007","unstructured":"Mahnke K, Johnson TS, Ring S, Enk AH (2007) Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 46:159\u2013167","journal-title":"J Dermatol Sci"},{"key":"1038_CR25","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.4049\/jimmunol.165.11.6244","volume":"165","author":"TL Warren","year":"2000","unstructured":"Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL et al (2000) APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 165:6244\u20136251","journal-title":"J Immunol"},{"key":"1038_CR26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1189\/jlb.1006606","volume":"81","author":"RC Gray","year":"2007","unstructured":"Gray RC, Kuchtey J, Harding CV (2007) CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J Leukoc Biol 81:1075\u20131085","journal-title":"J Leukoc Biol"},{"key":"1038_CR27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","volume":"157","author":"ZK Ballas","year":"1996","unstructured":"Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840\u20131845","journal-title":"J Immunol"},{"key":"1038_CR28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/sj.gt.3301010","volume":"6","author":"I Melero","year":"1999","unstructured":"Melero I, Duarte M, Ruiz J, Sangro B, Galofre J et al (1999) Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6:1779\u20131784","journal-title":"Gene Ther"},{"key":"1038_CR29","first-page":"4035","volume":"59","author":"Y Nishioka","year":"1999","unstructured":"Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H (1999) Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59:4035\u20134041","journal-title":"Cancer Res"},{"key":"1038_CR30","first-page":"228","volume":"61","author":"KA Candido","year":"2001","unstructured":"Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA et al (2001) Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61:228\u2013236","journal-title":"Cancer Res"},{"key":"1038_CR31","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","volume":"179","author":"J Li","year":"2007","unstructured":"Li J, Song W, Czerwinski DK, Varghese B, Uematsu S et al (2007) Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 179:2493\u20132500","journal-title":"J Immunol"},{"key":"1038_CR32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174","journal-title":"Nat Rev Immunol"},{"key":"1038_CR33","doi-asserted-by":"crossref","unstructured":"Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, et al (2011) CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res","DOI":"10.1158\/1078-0432.CCR-10-2672"},{"key":"1038_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/11316930-000000000-00000","volume":"23","author":"YM Murad","year":"2009","unstructured":"Murad YM, Clay TM (2009) CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 23:361\u2013375","journal-title":"BioDrugs"},{"key":"1038_CR35","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1158\/0008-5472.CAN-10-0905","volume":"70","author":"ZC Hartman","year":"2010","unstructured":"Hartman ZC, Osada T, Glass O, Yang XY, Lei GJ et al (2010) Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res 70:7209\u20137220","journal-title":"Cancer Res"},{"key":"1038_CR36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1215\/S1522851705000475","volume":"8","author":"A Carpentier","year":"2006","unstructured":"Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A et al (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8:60\u201366","journal-title":"Neuro Oncol"},{"key":"1038_CR37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CJI.0b013e3181ace876","volume":"32","author":"RJ Amato","year":"2009","unstructured":"Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S et al (2009) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 32:765\u2013772","journal-title":"J Immunother"},{"key":"1038_CR38","doi-asserted-by":"crossref","unstructured":"Krishnamachari Y, Geary SM, Lemke CD, Salem AK (2010) Nanoparticle Delivery systems in cancer vaccines. Pharm Res","DOI":"10.1007\/s11095-010-0241-4"},{"key":"1038_CR39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","volume":"3","author":"R Ramlau","year":"2008","unstructured":"Ramlau R, Quoix E, Rolski J, Pless M, Lena H et al (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV non-small cell lung cancer. J Thorac Oncol 3:735\u2013744","journal-title":"J Thorac Oncol"},{"key":"1038_CR40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.addr.2008.12.005","volume":"61","author":"DM Lubaroff","year":"2009","unstructured":"Lubaroff DM, Karan D (2009) CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev 61:268\u2013274","journal-title":"Adv Drug Deliv Rev"},{"key":"1038_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ymthe.2004.10.015","volume":"11","author":"Y Shen","year":"2005","unstructured":"Shen Y, Nemunaitis J (2005) Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 11:180\u2013195","journal-title":"Mol Ther"},{"key":"1038_CR42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CDLI.8.6.1131-1135.2001","volume":"8","author":"S Neri","year":"2001","unstructured":"Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8:1131\u20131135","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1038-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1038-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T02:56:52Z","timestamp":1686106612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,28]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1038-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,28]]}}}